Introduction Ovarian cancer is one of the most common malignant tumors in gynecology, with the highest mortality rate among gynecological malignancies. Despite continuous advancements in clinical surgery and ongoing optimization of chemotherapy regimens, the prognosis for patients with advanced ovarian cancer remains poor, especially for those who are resistant to platinum-based drugs, leaving limited treatment options and a short survival period. In recent years, the emergence of antibody-drug conjugates (ADCs) has brought revolutionary changes to the treatment of advanced ovarian cancer. These innovative drugs…